Junshi, Coherus gun for major PD-(L)1 market with PhIII NSCLC results
As a slate of made-in-China checkpoint inhibitors arrive on the scene, China-based drugmakers have shown time and again that they’re not content with just the Chinese market or niches of the American market. Rather, they are more than eager to follow the sprawling roadmap that leaders like Merck and Bristol Myers Squibb have offered — and dive right into large cancer indications.
For the latest example, look no further than Shanghai Junshi — the first biotech to steer a homegrown PD-(L)1 toward approval from China’s NMPA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.